|
gptkbp:instanceOf
|
gptkb:drug
alpha-1 blocker
|
|
gptkbp:approvedBy
|
1996
|
|
gptkbp:ATCCode
|
G04CA02
|
|
gptkbp:brand
|
gptkb:Omnic
Flomax
Urimax
|
|
gptkbp:CASNumber
|
106133-20-4
|
|
gptkbp:category
|
gptkb:Sulfonamides
Adrenergic antagonists
Carboxamides
Ethers
Methoxy compounds
Phenethylamines
Propyl compounds
Urologicals
|
|
gptkbp:contraindication
|
severe liver impairment
hypersensitivity to tamsulosin
|
|
gptkbp:developedBy
|
gptkb:Yamanouchi_Pharmaceutical
|
|
gptkbp:drugInteraction
|
gptkb:prazosin
gptkb:paroxetine
gptkb:warfarin
gptkb:erythromycin
gptkb:ketoconazole
cimetidine
phosphodiesterase inhibitors
doxazosin
terazosin
|
|
gptkbp:eliminationHalfLife
|
9–15 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:hasMolecularFormula
|
C20H28N2O5S
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Tamsulosin
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
selective alpha-1A adrenergic receptor antagonist
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:patentExpired
|
2009 (US)
|
|
gptkbp:pregnancyCategory
|
B (US)
B3 (Australia)
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:orthostatic_hypotension
gptkb:rhinitis
dizziness
headache
ejaculation disorder
|
|
gptkbp:usedFor
|
gptkb:benign_prostatic_hyperplasia
urinary retention
|
|
gptkbp:bfsParent
|
gptkb:Viatris
|
|
gptkbp:bfsLayer
|
8
|